ACT-335827

ACT-335827
Clinical data
Routes of
administration		Oral
Drug classOrexin 1 receptor antagonist
Identifiers
  • (R)-2-((S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-isopropyl-2-phenylacetamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC31H38N2O5
Molar mass518.654 g·mol−1
3D model (JSmol)
  • COC1=CC(C[C@@H](C2=C3)N(CCC2=CC(OC)=C3OC)[C@@H](C(NC(C)C)=O)C4=CC=CC=C4)=CC=C1OC
  • InChI=1S/C31H38N2O5/c1-20(2)32-31(34)30(22-10-8-7-9-11-22)33-15-14-23-18-28(37-5)29(38-6)19-24(23)25(33)16-21-12-13-26(35-3)27(17-21)36-4/h7-13,17-20,25,30H,14-16H2,1-6H3,(H,32,34)/t25-,30+/m0/s1
  • Key:HXHOBPVRRPCTLG-SETSBSEESA-N

ACT-335827 is an orally available, selective orexin 1 receptor antagonist with anxiolytic effects in animals. Unlike other orexin receptor antagonists, ACT-335827 lacks sedative effects and was found to have no impact on sleep architecture in mice.[1][2]

References

  1. ^ Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (June 2013). "Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist". ChemMedChem. 8 (6): 898–903. doi:10.1002/cmdc.201300003. PMID 23589487. S2CID 21644009.
  2. ^ Merlo Pich E, Melotto S (2014). "Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use". Frontiers in Neuroscience. 8: 26. doi:10.3389/fnins.2014.00026. PMC 3923148. PMID 24592206.



Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.